Compare PINE & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PINE | CABA |
|---|---|---|
| Founded | 2019 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 317.1M | 339.1M |
| IPO Year | 2019 | 2019 |
| Metric | PINE | CABA |
|---|---|---|
| Price | $16.63 | $1.29 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 10 |
| Target Price | ★ $19.70 | $11.75 |
| AVG Volume (30 Days) | 163.0K | ★ 4.6M |
| Earning Date | 10-22-2026 | 11-05-2026 |
| Dividend Yield | ★ 7.67% | N/A |
| EPS Growth | N/A | ★ 10.26 |
| EPS | ★ 0.42 | N/A |
| Revenue | ★ $60,532,000.00 | N/A |
| Revenue This Year | $31.91 | N/A |
| Revenue Next Year | $10.40 | N/A |
| P/E Ratio | $39.79 | ★ N/A |
| Revenue Growth | ★ 15.90 | N/A |
| 52 Week Low | $15.81 | $1.18 |
| 52 Week High | $21.99 | $4.23 |
| Indicator | PINE | CABA |
|---|---|---|
| Relative Strength Index (RSI) | 43.83 | 35.07 |
| Support Level | $16.62 | $1.18 |
| Resistance Level | $17.10 | $1.63 |
| Average True Range (ATR) | 0.44 | 0.13 |
| MACD | 0.06 | 0.03 |
| Stochastic Oscillator | 55.10 | 24.44 |
Alpine Income Property Trust Inc is a real estate investment trust (REIT) that owns and operates a high-quality portfolio of commercial net lease properties in the United States. The company's portfolio predominantly comprises single-tenant retail properties located in or near metropolitan statistical areas, or MSAs. It operates in two business segments: income properties, which derive maximum revenue, and commercial loans and investments.
Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.